Overview Dividends

(BCPC) Balchem - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0576652004

Choline, Encapsulated Nutrients, Sterilants, Propylene Oxide, Chelated Minerals

Specialty Chemicals
Market Cap in USD: 5,095m

IPO / Inception: 1986-06-03
Return 12m vs S&P 500: -19.7%

EPS (Earnings per Share)

EPS CAGR: -46.99%
EPS Trend: -17.6%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 6.25%
Rev. Trend: 76.0%

Last SUE: 1.65
Qual. Beats: 1

Dividends

Dividend Yield	0.62%
Yield on Cost 5y	0.86%
Yield CAGR 5y	10.78%
Payout Consistency	96.3%
Payout Ratio	36.8%

Risk via 5d forecast
Volatility	22.6%
Value at Risk 5%th	34.7%
Relative Tail Risk	-6.64%

Reward TTM
Sharpe Ratio	-0.36
Alpha	-17.02
CAGR/Max DD	0.41

Character TTM
Hurst Exponent	0.519
Beta	0.523
Beta Downside	0.438

Drawdowns 3y
Max DD	23.10%
Mean DD	8.41%
Median DD	8.49%

Description: BCPC Balchem November 05, 2025

Balchem Corporation (NASDAQ: BCPC) manufactures specialty performance ingredients for a broad set of markets-including human nutrition, animal health, and industrial sterilization-organized into three operating segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.

In FY 2023 the company generated roughly $2.2 billion in revenue, with an operating margin of about 12 % and a 5 % year-over-year increase driven primarily by higher demand for its vitamin K2 and microencapsulation platforms in functional foods and dietary supplements. A key sector catalyst is the accelerating consumer shift toward fortified, “clean-label” products, which is expanding the addressable market for Balchem’s spray-dried powders and lipid delivery systems. On the animal side, tighter regulations on antibiotic use are boosting adoption of chelated minerals and choline-based feed additives, supporting the segment’s double-digit growth trajectory.

For a deeper, data-rich assessment of Balchem’s valuation dynamics, you may find it worthwhile to explore the company’s profile on ValueRay, where additional quantitative metrics and scenario analyses are available.

Piotroski VR‑10 (Strict, 0-10) 8.0

Net Income (149.2m TTM) > 0 and > 6% of Revenue (6% = 60.8m TTM)

FCFTA 0.10 (>2.0%) and ΔFCFTA -0.45pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 21.44% (prev 22.98%; Δ -1.53pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.12 (>3.0%) and CFO 201.6m > Net Income 149.2m (YES >=105%, WARN >=100%)

Net Debt (90.7m) to EBITDA (260.1m) ratio: 0.35 <= 3.0 (WARN <= 3.5)

Current Ratio 2.72 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (32.7m) change vs 12m ago -0.25% (target <= -2.0% for YES)

Gross Margin 35.82% (prev 34.47%; Δ 1.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 62.22% (prev 59.01%; Δ 3.21pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 18.82 (EBITDA TTM 260.1m / Interest Expense TTM 10.9m) >= 6 (WARN >= 3)

Altman Z'' 7.23

(A) 0.13 = (Total Current Assets 343.7m - Total Current Liabilities 126.4m) / Total Assets 1.66b

(B) 0.67 = Retained Earnings (Balance) 1.11b / Total Assets 1.66b

(D) 3.19 = Book Value of Equity 1.16b / Total Liabilities 363.2m

Total Rating: 7.23 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 73.60

1. Piotroski 8.0pt

2. FCF Yield 3.12%

3. FCF Margin 15.94%

4. Debt/Equity 0.12

5. Debt/Ebitda 0.35

6. ROIC - WACC (= 3.46)%

7. RoE 12.12%

8. Rev. Trend 75.96%

9. EPS Trend -17.65%

What is the price of BCPC shares?

As of December 31, 2025, the stock is trading at USD 154.56 with a total of 92,538 shares traded.
Over the past week, the price has changed by -1.32%, over one month by -0.08%, over three months by +4.34% and over the past year by -5.16%.

Is BCPC a buy, sell or hold?

Balchem has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy BCPC.

Strong Buy: 0
Buy: 2
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the BCPC price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	191	23.6%
Analysts Target Price	191	23.6%
ValueRay Target Price	162.3	5%

BCPC Fundamental Data Overview December 24, 2025

Market Cap USD = 5.10b (5.10b USD * 1.0 USD.USD)
P/E Trailing = 34.3545
P/E Forward = 30.2115
P/S = 5.0274
P/B = 3.8975
P/EG = 4.8341
Beta = 0.993
Revenue TTM = 1.01b USD
EBIT TTM = 204.3m USD
EBITDA TTM = 260.1m USD
Long Term Debt = 154.0m USD (from longTermDebt, last quarter)
Short Term Debt = 202.0k USD (from shortTermDebt, last quarter)
Debt = 155.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 90.7m USD (from netDebt column, last quarter)
Enterprise Value = 5.19b USD (5.10b + Debt 155.8m - CCE 65.1m)
Interest Coverage Ratio = 18.82 (Ebit TTM 204.3m / Interest Expense TTM 10.9m)
FCF Yield = 3.12% (FCF TTM 161.6m / Enterprise Value 5.19b)
FCF Margin = 15.94% (FCF TTM 161.6m / Revenue TTM 1.01b)
Net Margin = 14.72% (Net Income TTM 149.2m / Revenue TTM 1.01b)
Gross Margin = 35.82% ((Revenue TTM 1.01b - Cost of Revenue TTM 650.5m) / Revenue TTM)
Gross Margin QoQ = 35.68% (prev 36.45%)
Tobins Q-Ratio = 3.12 (Enterprise Value 5.19b / Total Assets 1.66b)
Interest Expense / Debt = 1.51% (Interest Expense 2.35m / Debt 155.8m)
Taxrate = 22.59% (11.8m / 52.0m)
NOPAT = 158.2m (EBIT 204.3m * (1 - 22.59%))
Current Ratio = 2.72 (Total Current Assets 343.7m / Total Current Liabilities 126.4m)
Debt / Equity = 0.12 (Debt 155.8m / totalStockholderEquity, last quarter 1.30b)
Debt / EBITDA = 0.35 (Net Debt 90.7m / EBITDA 260.1m)
Debt / FCF = 0.56 (Net Debt 90.7m / FCF TTM 161.6m)
Total Stockholder Equity = 1.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.98% (Net Income 149.2m / Total Assets 1.66b)
RoE = 12.12% (Net Income TTM 149.2m / Total Stockholder Equity 1.23b)
RoCE = 14.75% (EBIT 204.3m / Capital Employed (Equity 1.23b + L.T.Debt 154.0m))
RoIC = 11.20% (NOPAT 158.2m / Invested Capital 1.41b)
WACC = 7.74% (E(5.10b)/V(5.25b) * Re(7.94%) + D(155.8m)/V(5.25b) * Rd(1.51%) * (1-Tc(0.23)))
Discount Rate = 7.94% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 0.35%
[DCF Debug] Terminal Value 80.77% ; FCFE base≈162.0m ; Y1≈190.6m ; Y5≈291.5m
Fair Price DCF = 154.3 (DCF Value 5.00b / Shares Outstanding 32.4m; 5y FCF grow 18.81% → 3.0% )
EPS Correlation: -17.65 | EPS CAGR: -46.99% | SUE: -4.0 | # QB: 0
Revenue Correlation: 75.96 | Revenue CAGR: 6.25% | SUE: 1.65 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.31 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=5.57 | Chg30d=+0.048 | Revisions Net=+1 | Growth EPS=+9.0% | Growth Revenue=+6.4%

Additional Sources for BCPC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle